» Articles » PMID: 24939901

A Gain-of-function Mouse Model Identifies PRMT6 As a NF-κB Coactivator

Overview
Specialty Biochemistry
Date 2014 Jun 19
PMID 24939901
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Protein arginine methyltransferase 6 (PRMT6) is a nuclear enzyme that modifies histone tails. To help elucidate the biological function of PRMT6 in vivo, we generated transgenic mice that ubiquitously express PRMT6 fused to the hormone-binding portion of the estrogen receptor (ER*). The ER*-PRMT6 fusion is unstable and cytoplasmic, but upon systemic treatment with tamoxifen, it becomes stabilized and translocates into the nucleus. As a result, a dramatic increase in the H3R2me2a histone mark is observed. We found that one consequence of induced ER*-PRMT6 activation is increased IL-6 levels. IL-6 expression is regulated by the nuclear factor-kappa B (NF-κB) transcription factor, and PRMT6 functions as a coactivator of this pathway. We show that PRMT6 directly interacts with RelA, and that its overexpression enhances the transcriptional activity of an ectopic NF-κB reporter and endogenously regulates NF-κB target genes. PRMT6 is recruited, by RelA, to selective NF-κB target promoters upon TNF-α stimulation. Moreover, ER*-PRMT6 activation causes RelA accumulation in the nucleus. In summary, we observe that PRMT6 is recruited to chromatin at selective NF-κB target promoters, where it likely impacts the histone code and/or methylates other chromatin-associated proteins to facilitate transcription.

Citing Articles

ID3 promotes erythroid differentiation and is repressed by a TAL1-PRMT6 complex.

Heller V, Wang L, Schneider E, Gerstner M, Bajer L, Decker R J Biol Chem. 2024; 301(2):108119.

PMID: 39716491 PMC: 11847539. DOI: 10.1016/j.jbc.2024.108119.


Protein arginine methyltransferase-6 regulates heterogeneous nuclear ribonucleoprotein-F expression and is a potential target for the treatment of neuropathic pain.

Zhang X, Liu Y, Xu F, Zhou C, Lu K, Fang B Neural Regen Res. 2024; 20(9):2682-2696.

PMID: 39503430 PMC: 11801299. DOI: 10.4103/NRR.NRR-D-23-01539.


Histone modifications and their roles in macrophage-mediated inflammation: a new target for diabetic wound healing.

Wang J, Feng J, Ni Y, Wang Y, Zhang T, Cao Y Front Immunol. 2024; 15:1450440.

PMID: 39229271 PMC: 11368794. DOI: 10.3389/fimmu.2024.1450440.


PRMT6 Epigenetically Drives Metabolic Switch from Fatty Acid Oxidation toward Glycolysis and Promotes Osteoclast Differentiation During Osteoporosis.

Chu W, Peng W, Lu Y, Liu Y, Li Q, Wang H Adv Sci (Weinh). 2024; 11(40):e2403177.

PMID: 39120025 PMC: 11516099. DOI: 10.1002/advs.202403177.


Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia.

Sauter C, Morin T, Guidez F, Simonet J, Fournier C, Row C Commun Biol. 2024; 7(1):753.

PMID: 38902349 PMC: 11190286. DOI: 10.1038/s42003-024-06453-6.


References
1.
Hayden M, Ghosh S . NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26(3):203-34. PMC: 3278889. DOI: 10.1101/gad.183434.111. View

2.
McMahon M . Steroid receptor fusion proteins for conditional activation of Raf-MEK-ERK signaling pathway. Methods Enzymol. 2001; 332:401-17. DOI: 10.1016/s0076-6879(01)32218-8. View

3.
Niwa H, Yamamura K, Miyazaki J . Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991; 108(2):193-9. DOI: 10.1016/0378-1119(91)90434-d. View

4.
Mattioni T, Louvion J, Picard D . Regulation of protein activities by fusion to steroid binding domains. Methods Cell Biol. 1994; 43 Pt A:335-52. DOI: 10.1016/s0091-679x(08)60611-1. View

5.
Hyllus D, Stein C, Schnabel K, Schiltz E, Imhof A, Dou Y . PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev. 2007; 21(24):3369-80. PMC: 2113036. DOI: 10.1101/gad.447007. View